CXCR1 participates in bone cancer pain induced by Walker 256 breast cancer cells in female rats.
Chengfei XuBaoxia ZhaoLongsheng XuYahui WangBeibei LiuMiao XuQiuli HeChaobo NiJie FuMin KongXuewu LinHuadong NiMing YaoPublished in: Molecular pain (2022)
Bone cancer pain (BCP) is a clinically intractable mixed pain, involving inflammation and neuropathic pain, and its mechanisms remain unclear. CXC chemokine receptor 1 (CXCR1, IL-8RA) and 2 (CXCR2, IL-8RB) are high-affinity receptors for interleukin 8 (IL8). According to previous studies, CXCR2 plays a crucial role in BCP between astrocytes and neurons, while the role of CXCR1 remains unclear. The objective of this study was to investigate the role of CXCR1 in BCP. We found that CXCR1 expression increased in the spinal dorsal horn. Intrathecal injection of CXCR1 siRNA effectively attenuated mechanical allodynia and pain-related behaviors in rats. It was found that CXCR1 was predominantly co-localized with neurons. Intrathecal injection of CXCR1-siRNA reduced phosphorylated JAK2/STAT3 protein levels and the NLRP3 inflammasome (NLRP3, caspase1, and IL-1β) levels. Furthermore, in vitro cytological experiments confirmed this conclusion. The study results suggest that the spinal chemokine receptor CXCR1 activation mediates BCP through JAK2/STAT3 signaling pathway and NLRP3 inflammasome (NLRP3, caspase1, and IL-1β).
Keyphrases
- neuropathic pain
- spinal cord
- nlrp inflammasome
- cell migration
- spinal cord injury
- chronic pain
- pain management
- signaling pathway
- rheumatoid arthritis
- cell death
- breast cancer cells
- squamous cell carcinoma
- epithelial mesenchymal transition
- binding protein
- bone mineral density
- body composition
- small molecule
- long non coding rna
- squamous cell
- cancer therapy
- soft tissue
- drug delivery
- idiopathic pulmonary fibrosis
- drug induced
- bone loss